
Andrew Alexis, MD, MPH, highlights positive lebrikizumab-lbkz data for atopic dermatitis
Recent 24-week data from the ADmirable study reinforce the safety and efficacy of lebrikizumab-lbkz (EBGLYSS; Eli Lilly) in adolescents and adults with moderate-to-severe atopic dermatitis (AD), including individuals with pigmented skin tones. Findings …